Regenerative Medical Technology Group Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.1M | $4.1M | $2.4M | $1.5M | $437.9K | $55.1K | $30.1K | $50.1K |
| Cost of Revenue | $2.3M | $1.3M | $734.3K | $653.3K | $287.8K | $44.0K | $55.5K | $68.3K |
| Gross Profit | $2.8M | $2.8M | $1.7M | $877.0K | $150.1K | $11.1K | $-25.4K | $-18.2K |
| Gross Margin | 55.1% | 68.7% | 69.5% | 57.3% | 34.3% | 20.2% | -84.4% | -36.4% |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | $1.1M | $798.3K | $752.5K | $8.2M | $149.4K | $29.9K | $31.4K | $43.1K |
| Operating Income | $-867.2K | $81.2K | $-715.2K | — | — | — | — | — |
| Operating Margin | -17.0% | 2.0% | -29.7% | — | — | — | — | — |
| Interest Expense | — | — | — | — | $2.7M | $4.2M | $571.0K | $528.4K |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | $-1.6M | $-1.2M | $-2.1M | $-1.2M | $-2.7M | — | — | — |
| Net Income | $-7.8M | $-5.6M | $-9.8M | $-5.5M | $-12.9M | $-5.9M | $-2.5M | $-2.1M |
| Net Margin | -153.2% | -135.4% | -407.2% | -359.9% | -2,942.4% | -10,703.5% | -8,335.2% | -4,105.6% |
| EPS (Basic) | $-0.62 | $-0.44 | $-0.79 | $-0.45 | $-1.12 | $-0.63 | $-0.47 | $-0.50 |
| EPS (Diluted) | $-0.62 | $-0.44 | $-0.79 | $-0.45 | $-1.12 | $-0.63 | $-0.47 | $-0.50 |
| Shares Outstanding (Basic) | 12.6M | 12.5M | 12.4M | 12.2M | 11.5M | 9.3M | 5.3M | 4.1M |
| Shares Outstanding (Diluted) | 12.6M | 12.5M | 12.4M | 12.2M | 11.5M | 9.3M | 5.3M | 4.1M |
| Dividends Per Share | — | — | — | — | — | — | — | — |